From Yahoo Finance: 2025-05-16 17:20:00

Viking Therapeutics stock rose 3% following news of Novo Nordisk CEO’s departure. Viking gained fame with its weight-loss drug VK2735. Leadership changes can impact business momentum, but investors should focus on drug progress. The stock reaction may be overdone, as Novo Nordisk will likely carefully replace its CEO.

Consider that Viking Therapeutics wasn’t among the Motley Fool’s top 10 stock picks. Stock Advisor’s total average return is 967%, outperforming the S&P 500. Don’t miss out on the latest top 10 list by joining Stock Advisor for potential monster returns.

Read more: Why Viking Therapeutics Stock Bumped 3% Higher Today